Search results for "Amide"

showing 10 items of 3119 documents

Altered endocannabinoid-dynamics in craniopharyngioma patients and their association with HPA-axis disturbances.

2021

Objective Patients with craniopharyngioma (CP) frequently suffer from morbid obesity. Endocannabinoids (ECs) are involved in weight gain and rewarding behavior but have not been investigated in this context. Design Cross-sectional single-center study. Methods Eighteen patients with CP and 16 age- and sex-matched controls were included. Differences in endocannabinoids (2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (AEA)) and endocannabinoid-like molecules (oleoyl ethanolamide (OEA), palmitoylethanolamide (PEA), and arachidonic acid (AA) were measured at baseline and following endurance exercise. We further explored ECs-dynamics in relation to markers of HPA-axis activity (ACT…

AdultMalemedicine.medical_specialtyHypothalamo-Hypophyseal SystemHydrocortisonePolyunsaturated AlkamidesEndocrinology Diabetes and MetabolismHypothalamusContext (language use)Oleic AcidsArachidonic AcidsGlycerideschemistry.chemical_compoundCraniopharyngiomaYoung AdultEndocrinologyCopeptinAdrenocorticotropic HormoneEndurance trainingInternal medicinemedicineEthanolamideHumansPituitary NeoplasmsExerciseArachidonic Acidbusiness.industryGlycopeptidesGeneral MedicineMiddle Agedmedicine.diseaseEndocannabinoid systemCraniopharyngiomaEndurance TrainingEndocrinologyCross-Sectional StudieschemistryCase-Control StudiesArachidonic acidFemalemedicine.symptombusinessWeight gainEndocannabinoidsEuropean journal of endocrinology
researchProduct

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis:A Randomized, Placebo-Controlled, Phase II Study

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc-related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3-week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

AdultMalemedicine.medical_specialtyImmunologyPhases of clinical researchSelexipagPlaceboSeverity of Illness Indexlaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDouble-Blind MethodRheumatologyRandomized controlled triallawInternal medicineAcetamidesSeverity of illnessClinical endpointHumansImmunology and AllergyMedicine030212 general & internal medicineAdverse effectAntihypertensive Agents030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryBayes TheoremRaynaud DiseaseMiddle AgedClinical trialTreatment OutcomechemistryPyrazinesFemalebusiness
researchProduct

Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary fin…

2007

The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group I (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and C…

AdultMalemedicine.medical_specialtyIndomethacinPlaceboGastroenterologyElectrocardiographyPericarditisAcute pericarditisDouble-Blind MethodRecurrenceInternal medicineTroponin ImedicineHumansPericarditisRosuvastatinRosuvastatin CalciumPericarditis Colchicine Postpericardiotomy syndromeFirst episodeSulfonamidesmedicine.diagnostic_testbiologybusiness.industryAnti-Inflammatory Agents Non-SteroidalCardiovascular AgentsGeneral Medicinemedicine.diseaseSurgeryFluorobenzenesC-Reactive ProteinPyrimidinesTreatment OutcomeErythrocyte sedimentation rateAcute Diseasebiology.proteinDrug Therapy CombinationFemaleCreatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsbusinessFollow-Up Studiesmedicine.drugClinical Science
researchProduct

Experience in the long term use of new antiarrhythmic drugs.

1985

Meinertz et a1. (1984) investigated the long term efficacy and tolerability of flecainide in patients with ventricular arrhythmias. 15 patients were studied, 8 women and 7 men, aged 19 to 74 (mean 58.7) years, with more than 30 ventricular premature complexes (VPCs) per hour, and ventricular arrhythmias of Lown grade IVA or IVB. 11 had coronary artery disease and 2 had idiopathic dilated cardiomyopathy. Patients were excluded on the basis of sustained ventricular tachycardia (VT) [defined as ~ 3 consecutive beats at a rate of> 100 beats/min]; myocardial infarction within the last 6 months; unstable angina; severe congestive heart failure; or conduction abnormalities. Previously unsuccessful…

AdultMalemedicine.medical_specialtyLidocainePropafenonePharmacologyLorcainidePiperidinesInternal medicineMexiletineIdiopathic dilated cardiomyopathymedicineHumansPharmacology (medical)cardiovascular diseasesMyocardial infarctionFlecainideAgedFlecainidebusiness.industryArrhythmias CardiacMiddle Agedmedicine.diseasecardiovascular systemCardiologyFemaleDisopyramidebusinessAnti-Arrhythmia Agentsmedicine.drugDrugs
researchProduct

Influence of loperamide and loperamide oxide on the anal sphincter

1992

The objective of this study was to investigate the effects of the opioid loperamide and its recently synthesized pharmacologically inactive prodrug loperamide oxide on the anal sphincter. In a double-blind, placebo-controlled crossover study, anorectal manometry was performed in 12 healthy volunteers five hours after oral bolus application of 10 mg of loperamide, loperamide oxide, or placebo. Loperamide significantly increased the threshold volumes for minimal perception and urgency to defecate (P less than 0.05) and raised the volume required to abolish recovery of the rectoanal inhibitory reflex (P less than 0.05). These findings suggest that loperamide has a specific continence-improving…

AdultMalemedicine.medical_specialtyLoperamideManometryAnal CanalPlaceboLoperamideGastroenterologyBolus (medicine)Double-Blind MethodInternal medicinePressuremedicineHumansDefecationbusiness.industryAnorectal manometryRectumGastroenterologyGeneral MedicineProdrugCrossover studyOpioidDefecationFemalebusinessmedicine.drugDiseases of the Colon & Rectum
researchProduct

Study of abnormal adrenal receptors in subjects with ACTH-independent Cushing's syndrome and nodular adrenal hyperplasia

2020

ACTH-independent Cushing's Syndrome (AICS) accounts for 15-20% of cases of Cushing's syndrome, with1% due to abnormal receptors. Our aim is to study the presence of abnormal receptors in subjects diagnosed with AICS with nodular adrenal hyperplasia in a 14-year period (2002-2016), as well as its clinical-biological and evolutive characteristics.A multicentre descriptive study of a 15-case series of AICS with nodular adrenal hyperplasia (study period: 2002-2016). In these cases, abnormal receptor screening was performed by means of stimulation tests, with a plasma cortisol increase of ≥ 25% from baseline being considered pathologic.Of the 15 cases, 13 were female, with a mean age at diagnosi…

AdultMalemedicine.medical_specialtyMetoclopramide030209 endocrinology & metabolism030204 cardiovascular system & hematologyGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineAdrenal GlandsmedicineMeal testHumansDesmopressinReceptorCushing SyndromeAgedHyperplasiaS syndromebusiness.industryMiddle AgedHyperplasiamedicine.diseaseFemaleBilateral adrenalectomyTerlipressinbusinessmedicine.drugEndocrinología, Diabetes y Nutrición (English ed.)
researchProduct

Stratified Care vs Step Care Strategies for Migraine

2000

ContextVarious guidelines recommend different strategies for selecting and sequencing acute treatments for migraine. In step care, treatment is escalated after first-line medications fail. In stratified care, initial treatment is based on measurement of the severity of illness or other factors. These strategies for migraine have not been rigorously evaluated.ObjectiveTo compare the clinical benefits of 3 strategies: stratified care, step care within attacks, and step care across attacks, among patients with migraine.Design and SettingRandomized, controlled, parallel-group clinical trial conducted by the Disability in Strategies Study group from December 1997 to March 1999 in 88 clinical cen…

AdultMalemedicine.medical_specialtyMetoclopramideMigraine DisordersPopulationZolmitriptanSeverity of Illness IndexDrug Administration Schedulelaw.inventionRandomized controlled triallawInternal medicineSeverity of illnessHumansMedicineeducationOxazolidinonesAspirineducation.field_of_studyAspirinbusiness.industryAnti-Inflammatory Agents Non-SteroidalArea under the curveGeneral MedicineMiddle Agedmedicine.diseaseTryptaminesSerotonin Receptor AgonistsClinical trialMigraineCritical PathwaysPhysical therapyDopamine AntagonistsFemalebusinessmedicine.drugJAMA
researchProduct

Aggressive Pharmacological Treatment for Reversing Malignant Bowel Obstruction

2004

Early and intensive pharmacological treatment not only may reduce gastrointestinal symptoms but also reverse malignant bowel obstruction. Fifteen consecutive advanced cancer patients with inoperable bowel obstruction received a combination of drugs including metoclopramide, octreotide, dexamethasone and an initial bolus of amidotrizoato. Recovery of intestinal transit was reported within 1-5 days in fourteen patients, who continued this treatment without presenting symptoms of bowel obstruction until death. This case series establishes that the combination of propulsive and antisecretive agents can act synergistically to allow a fast recovery of bowel transit without inducing unpleasant col…

AdultMalemedicine.medical_specialtyMetoclopramidemedicine.drug_classOctreotideGastroenterologyBolus (medicine)Gastrointestinal AgentsInternal medicineEdemamedicineHumansGeneral NursingDexamethasoneAgedPelvic NeoplasmsTerminal Carebusiness.industrydigestive oral and skin physiologyPalliative CareFecal impactionDrug SynergismRecovery of FunctionMiddle Agedmedicine.diseasedigestive system diseasesBowel obstructionDrug CombinationsAnesthesiology and Pain MedicineTreatment OutcomeAnesthesiaAbdominal NeoplasmsCorticosteroidAntiemeticsFemaleNeurology (clinical)medicine.symptombusinessIntestinal Obstructionmedicine.drug
researchProduct

A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction

1993

A double-blind parallel-group comparison study of moclobemide versus doxepin in 237 patients with major depression confirmed that moclobemide was equal in efficacy and better tolerated than doxepin. It was less sedating and caused fewer anticholinergic adverse events as measured by the UKU side-effect rating scale. Unexpectedly, moclobemide therapy more often than doxepin resulted in increased sexual desire. An exploratory analysis of UKU-measured symptoms of impaired sexual function prior to commencement of the study revealed that moclobemide more often than doxepin led to an improvement of reduced libido and impaired erection, ejaculation and orgasm. This finding is compatible with the as…

AdultMalemedicine.medical_specialtyMonoamine Oxidase InhibitorsPersonality Inventorymedicine.drug_classLibidoMoclobemideSexual BehaviorDouble-Blind MethodMoclobemidemedicineAnticholinergicHumansPharmacology (medical)PsychiatryAdverse effectDepression (differential diagnoses)Depressive DisorderDose-Response Relationship DrugMiddle AgedDoxepinPsychiatry and Mental healthSexual dysfunctionAnesthesiaBenzamidesComparison studyFemaleDoxepinmedicine.symptomPsychologymedicine.drugInternational Clinical Psychopharmacology
researchProduct

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

2010

On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia.Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days of each 28-day treatment course with or without rituximab (375 mg/m(2) on day 0 of first course, and 500 mg/m(2) on da…

AdultMalemedicine.medical_specialtyNeutropeniaFCR RegimenKaplan-Meier EstimateOfatumumabSeverity of Illness IndexGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Monoclonal Murine-Derivedchemistry.chemical_compoundChemoimmunotherapyObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansImmunologic FactorsMedicineCyclophosphamideAgedAged 80 and overbusiness.industryIncidenceAntibodies MonoclonalLeukopeniaGeneral MedicineMiddle AgedLeukemia Lymphocytic Chronic B-CellSurgeryFludarabineTreatment OutcomechemistryDisease ProgressionFemaleRituximabRefractory Chronic Lymphocytic LeukemiaRituximabbusinessVidarabineUntreated Chronic Lymphocytic Leukemiamedicine.drug
researchProduct